Theriva Biologics director awarded 75,000 stock options at $0.241

Theriva Biologics, Inc. director John J. Monahan reported a new stock option grant.

Rhea-AI Filing Summary

Theriva Biologics, Inc. director John J. Monahan reported a new stock option grant. On 01/05/2026 he received stock options to buy 75,000 shares of common stock at an exercise price of $0.241 per share. The options become exercisable starting 02/01/2026 and expire on 01/04/2033. They vest on a pro rata monthly basis over 12 months, which means a portion of the options becomes available to exercise each month during the first year.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 1 txn

Insider MONAHAN JOHN J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	75,000	$0.00	$0.00

Holdings After Transaction: Stock Options (right to buy) — 75,000 contracts (Direct)

Footnotes (1)

1. F1. These stock options vest pro rata on a monthly basis over 12 months.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Theriva Biologics (TOVX) report?

Theriva Biologics reported that director John J. Monahan received a grant of 75,000 stock options on 01/05/2026.

What is the exercise price of the new Theriva Biologics (TOVX) stock options?

The stock options granted to director John J. Monahan have an exercise price of $0.241 per share for Theriva Biologics common stock.

How do the new Theriva Biologics (TOVX) stock options vest?

The 75,000 stock options vest pro rata on a monthly basis over 12 months, so a portion becomes exercisable each month during the first year.

When do the Theriva Biologics (TOVX) options become exercisable and when do they expire?

The stock options become exercisable starting on 02/01/2026 and have an expiration date of 01/04/2033, if not exercised earlier.

Who is the reporting person in this Theriva Biologics (TOVX) insider filing?

The reporting person is John J. Monahan, who is identified as a director of Theriva Biologics, Inc.

What type of security was granted in the Theriva Biologics (TOVX) Form 4?

The filing reports a grant of stock options (right to buy) Theriva Biologics common stock, covering 75,000 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/06/2026 - 04:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MONAHAN JOHN J

(Last) (First) (Middle)

C/O THERIVA BIOLOGICS, INC., 9605

MEDICAL CENTER DRIVE, SUITE 270

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Theriva Biologics, Inc. [ TOVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$0.241	01/05/2026		A		75,000(1)		02/01/2026(1)	01/04/2033	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. These stock options vest pro rata on a monthly basis over 12 months.

	/s/ John J. Monahan	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.